	US 12,201,632 B2
	Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism
Fred Cohen, Washington Crossing, PA (US)
Assigned to STRONGBRIDGE DUBLIN LIMITED, Dublin (IE)
Filed by Strongbridge Dublin Limited, Chicago, IL (US)
Filed on Apr. 9, 2021, as Appl. No. 17/226,640.
Application 17/226,640 is a continuation of application No. PCT/IB2019/001105, filed on Oct. 11, 2019.
Claims priority of provisional application 62/744,958, filed on Oct. 12, 2018.
Prior Publication US 2021/0220352 A1, Jul. 22, 2021
Int. Cl. A61K 31/496 (2006.01); A61K 45/06 (2006.01); A61P 5/28 (2006.01); A61P 5/38 (2006.01)

CPC A61K 31/496 (2013.01) [A61K 45/06 (2013.01); A61P 5/28 (2018.01); A61P 5/38 (2018.01)]

16 Claims

1. A method for treating congenital adrenal hyperplasia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 2S,4R ketoconazole enantiomer, wherein the ketoconazole content of the therapeutically effective amount comprises less than 20% 2R,4S enantiomer and more than 80% 2S,4R enantiomer, and wherein 11-deoxycortisol (11-DOC) secretion is not substantially increased after administration of the 2S, 4R ketoconazole enantiomer.